Nausea, vomiting, or diarrhea during your first weeks on semaglutide or tirzepatide also increase contraceptive unreliability
Attendees will gain insights into OGDs role in advancing access to high quality, safe and effective generic drugs through transparent communication, shared scientific standards, and cross-border regulatory alignment for complex generic medicines
Ongoing clinical support helps interpret your individual response and optimize timing for dose changes or compound adjustments
Blood-sugar control In the head-to-head SURPASS-2 trial, lowered HbA1c more than semaglutide 1 mg
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg for 4 weeks (a non-therapeutic initiation dose to improve tolerability), then increased every 4 weeks to reach a therapeutic dose of 5-15 mg weekly based on response and tolerability
Measuring disease activity to predict therapeutic outcome in Graves ophthalmopathy